ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

Brian Leyland-Jones, Kathryn P. Gray, Mark Abramovitz, Mark Bouzyk, Brandon Young, Bradley Long, Roswitha Kammler, Patrizia Dell’Orto, Beat Thürlimann, Vernon Harvey, Patrick Neven, Laurent Arnould, Rudolf Maibach, Karen N. Price, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber, Olivia Pagani, Giuseppe Viale, James M. Rae and Meredith M. Regan; on behalf of the BIG 1-98 Collaborative Group.

Breast Cancer Res Treat. 2015 Dec;154(3):543-55.

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail